title: Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review.
authors.affiliation: Toronto Health Economics and Technology Assessment Collaborative and Institute for Work and Health, Toronto, Ontario, Canada. gabrielle.vandervelde@theta.utoronto.ca
authors.forename: Gabrielle
authors.initials: G
authors.lastname: van der Velde
authors.forename: Ba'
authors.initials: B
authors.lastname: Pham
authors.forename: Márcio
authors.initials: M
authors.lastname: Machado
authors.forename: Luciano
authors.initials: L
authors.lastname: Ieraci
authors.forename: William
authors.initials: W
authors.lastname: Witteman
authors.forename: Claire
authors.initials: C
authors.lastname: Bombardier
authors.forename: Murray
authors.initials: M
authors.lastname: Krahn
mesh_terms: D000818:Animals; D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000191:economics / Q000639:trends; D006801:Humans; D007155:Immunologic Factors / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D018501:Antirheumatic Agents; D007155:Immunologic Factors